European Pharmaceutical Review

OCTOBER 17, 2024

This decision was granted a couple of weeks following approval by the US and Drug Administration (FDA). Thus, ARS Pharmaceuticals anticipates approval by Q1 2025 in the UK and launch by summer 2025. What are the main advantages of EURneffy over similar treatments? Motohiro E, Kento T, Kyohei T , et al.

Food and Drug Administration 121

Food and Drug Administration Medicine Consulting Food 121

pharmaphorum

SEPTEMBER 21, 2022

The European Commission has followed the lead of the US FDA and approved AstraZeneca’s Tezspire as an add-on maintenance therapy for patients with severe asthma, becoming the first and only biologic that can be used in all patients, and not restricted to those with specific forms of the disease. billion or more.

Sales 108

Sales Patients Biopharma Medicine 108

pharmaphorum

SEPTEMBER 14, 2022

SparingVision’s lead candidates are both targeting inherited retinal diseases (IRDs), a group which already has a gene therapy on the market in Novartis’ Luxturna (voretigene neparvovec), which was approved by the FDA in 2017 for biallelic RPE65 mutation-associated retinal dystrophy, a group which includes a small group of RP patients.

Safety 52

Safety Leads Patients FDA 52

pharmaphorum

DECEMBER 14, 2022

Sodium oxybate — which in the late 1980s was marketed to bodybuilders and then became known as GHB and criminally used as a date rape drug — has been sold under the brand name Xyrem after gaining FDA approval in 2002. In 2020, the FDA-approved indication was expanded to include those patients who suffer from cataplexy.

Competition 95

Competition FDA Pharmaceutical Marketing 95

pharmaphorum

SEPTEMBER 11, 2022

The US FDA has cleared the first-in-class tyrosine kinase 2 (Tyk2) inhibitor as Sotyktu , and BMS says it now plans to launch the new drug later this month, aiming to mount a challenge to Amgen’s $2.3 billion oral psoriasis therapy Otezla (apremilast).

FDA 52

FDA Marketing Patients Sales 52

Medgadget

SEPTEMBER 29, 2023

We aim to optimize the device’s design for enhanced safety, reliability, and patient comfort and are targeting FDA IND submission and approval in late 2024 to conduct a Phase I first-in-human study in 2025.

Medicine 105

Medicine Distribution Specialization Medical 105

European Pharmaceutical Review

JUNE 27, 2024

Looking back briefly to 2023, within the cell and gene therapy space, the US Food and Drug Administration (FDA) approved marketing authorisations for seven of these treatments. In May and June, regulatory approvals have so far included treatments for rare disorders as well as in oncology, such as blood, endometrial and colorectal cancers.

Food and Drug Administration 64

Food and Drug Administration Food Patients Marketing 64

Clarivate

AUGUST 27, 2024

FDA approval in January 2024. reported having already switched 50% to 70% of their cardiac ablations to PFA – just two months after the launch of the two currently FDA-approved systems, Medtronic plc’s PulseSelect and Boston Scientific Corp.’s Boston Scientific Corp. received CE mark (i.e., in December 2023. s Farapulse.

Marketing 52

Marketing Competition FDA Electronics 52

Pharmaceutical Technology

JANUARY 8, 2023

Since then, the US FDA, EMA, and other agencies have approved several biologic antibodies targeting the inflammatory cytokines IL-4, IL-13, IL-5, and others for asthma. In 2018, the FDA rejected the approval application for GSK’s Nucala (mepolizumab) in COPD. Still, patients require an individual-led approach. Ongoing efforts.

Patients 119

Patients FDA Pharmaceutical Pharma 119

European Pharmaceutical Review

MARCH 14, 2024

For IgA nephropathy (IgAN), key highlights include the US Food And Drug Administration (FDA) approval of Calliditas Therapeutics’ TARPEYO and the Committee for Medicinal Products for Human Use (CHMP)’s recommendation of a conditional marketing authorisation for Filspari (sparsentan). Internet] Vera Therapeutics. cited 2024Mar].

Food and Drug Administration 98

Food and Drug Administration Leads Patients Side effects 98

European Pharmaceutical Review

MARCH 14, 2024

For IgA nephropathy (IgAN), key highlights include the US Food And Drug Administration (FDA) approval of Calliditas Therapeutics’ TARPEYO and the Committee for Medicinal Products for Human Use (CHMP)’s recommendation of a conditional marketing authorisation for Filspari (sparsentan). Internet] Vera Therapeutics. cited 2024Mar].

Food and Drug Administration 98

Food and Drug Administration Leads Patients Side effects 98

pharmaphorum

NOVEMBER 25, 2022

The Parma site, as yet only nine months into construction, is due to become operational from 2024, with FDA, IFA, and EMA approvals due to be sought for 2025. Going beyond the standards of care; improving drug safety and efficacy. But to make people safe requires a lot of research.

Pharmaceutical 94

Pharmaceutical Manufacturing Medicine Competition 94

Pharmaceutical Technology

JULY 29, 2022

On 25 June, Pfizer and BioNTech (Mainz, Germany) reported pivotal Phase II/III data demonstrating the safety, tolerability and immunogenicity of two Omicron-adapted vaccine candidates. The EMA started a rolling review for this Omicron-adapted vaccine on 27 June and the FDA plans to review the vaccine for EUA. 1 sub-lineage on 19 July.

Manufacturing 52

Manufacturing Food and Drug Administration Marketing FDA 52

Clarivate

OCTOBER 10, 2022

Based on the TROPICS-02 trial results, Gilead has submitted a supplemental biologics license application (sBLA) to the FDA, seeking a label expansion for TRODELVY in the much larger setting of metastatic HR+/HER2-negative breast cancer. Key ESMO findings. months; HR: 0.321, P<0.001). months; HR: 0.321, P<0.001). Market impact.

Marketing 52

Marketing Safety Patients Competition 52

Clarify Health

JULY 13, 2020

By 2025, several new gene and cell therapies will be coming to market. They narrowed the eligibility criteria, much beyond what was approved by the FDA. Despite their efficacy and safety, the high cost and lifetime use made payers put up barriers to exclude the drug on formulary. With a record-setting price of $2.1

Pharmaceutical 52

Pharmaceutical Pharma Patients Marketing 52

PM360

AUGUST 9, 2022

billion in 2025. Needles cause patients pain, anxiety, pose safety risks, and for some people receiving injection therapy is a traumatic experience. The FDA 510(k) submission is expected to take place in Quarter 3 2023. from 2021 and reach $4.2 Furthermore, it is estimated to reach $6.5 billion in 2030 at a CAGR of 9.2%.

Prescription 105

Prescription Medical Patients Side effects 105

Pharmaceutical Technology

DECEMBER 21, 2022

This could spell high-stake consequences for consumers whose privacy and safety could be at risk if AI models are not regulated. According to GlobalData, global AI revenues in the pharmaceutical, medical, and healthcare sectors are expected to reach almost $21 billion by 2025. FDA and EMA action.

Pharma 140

Pharma Pharmaceutical Medicine Government 140

Pharmaceutical Technology

APRIL 20, 2023

Following a tumultuous development cycle, DBV Technologies will now have to conduct an additional safety study of its peanut allergy Viaskin patch in toddlers ages 1–3 years, based on written correspondence from the US Food and Drug Administration (FDA). DBV expects to share topline data from the study in H1 2025.

Food and Drug Administration 52

Food and Drug Administration FDA Safety Prospecting 52

Pharmaceutical Technology

MARCH 22, 2023

According to the GlobalData report Contract Injectable Packaging Trends in the Bio/Pharma Industry , more than half (55%) of FDA drug approvals in 2021 were accounted for by injectables. From 2025, it will be substituted with a new chapter on functional tests for the complete system.” The demand for injectable drugs is rising.

Pharma 52

Pharma Manufacturing Key account management Marketing 52